UroGen Pharma Files 8-K for Reg FD Disclosure, Exhibits

Ticker: URGN · Form: 8-K · Filed: 2024-02-07T00:00:00.000Z

Sentiment: neutral

Topics: regulation-fd, disclosure, corporate-governance

TL;DR

**UroGen Pharma just dropped an 8-K for Reg FD, so new info is out.**

AI Summary

UroGen Pharma Ltd. filed an 8-K on February 7, 2024, primarily to disclose information under Regulation FD and to include financial statements and exhibits. This filing, with a Commission File Number of 001-38079, indicates that the company is making public certain information that may be material, ensuring fair disclosure to all investors. For shareholders, this means UroGen is transparently sharing updates that could influence their investment decisions, potentially impacting stock valuation based on the nature of the undisclosed information.

Why It Matters

This filing ensures all investors receive material information simultaneously, preventing selective disclosure and promoting a fair market for UroGen Pharma's stock.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure filing under Regulation FD, indicating transparency rather than a specific new risk.

Analyst Insight

Investors should review the specific content of the Regulation FD disclosure and any accompanying financial statements or exhibits to understand the new information UroGen Pharma is making public, as this could impact their investment thesis.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of UroGen Pharma Ltd.'s 8-K filing on February 7, 2024?

The primary purpose of UroGen Pharma Ltd.'s 8-K filing on February 7, 2024, is to disclose information under Regulation FD and to include financial statements and exhibits, as stated in the 'ITEM INFORMATION' section.

What is UroGen Pharma Ltd.'s trading symbol and on which exchange are its securities registered?

UroGen Pharma Ltd.'s trading symbol is URGN, and its Ordinary Shares, par value NIS0.01 per share, are registered on The Nasdaq Stock Market LLC, as indicated under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the business address and phone number of UroGen Pharma Ltd. as listed in the filing?

The business address of UroGen Pharma Ltd. is 400 Alexander Park Drive, 4th Floor, Princeton, New Jersey, 08540, and its telephone number is +1 (646) 768-9780, according to the filing's cover page.

Is UroGen Pharma Ltd. classified as an emerging growth company according to this 8-K filing?

No, UroGen Pharma Ltd. is not classified as an emerging growth company, as indicated by the unchecked box next to 'Emerging growth company' on the cover page of the 8-K.

What is the state or other jurisdiction of incorporation for UroGen Pharma Ltd.?

UroGen Pharma Ltd. is incorporated in Israel, as specified under 'State or other jurisdiction of incorporation' on the cover page of the 8-K.

Filing Stats: 492 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-02-07 16:15:51

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibit No. Description 99.1 Company Presentation, dated February 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 7, 2024 UROGEN PHARMA LTD. By: /s/ Don Kim Don Kim Chief Financial Officer

View on Read The Filing